The latest update is out from BioCardia ( (BCDA) ).
On March 31, 2025, BioCardia announced the two-year outcomes of its Phase 3 CardiAMP-HF study, revealing that its autologous cell therapy significantly improved survival, reduced major adverse cardiac and cerebrovascular events, and enhanced quality of life in ischemic heart failure patients with reduced ejection fraction. The study, involving 115 patients across 18 centers in the U.S. and Canada, showed particularly strong results in patients with elevated NTproBNP biomarkers, indicating the therapy’s potential to address a significant unmet need in heart failure treatment and reduce healthcare costs.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. The company develops biotherapeutic platforms such as CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
YTD Price Performance: 23.89%
Average Trading Volume: 49,634
Technical Sentiment Signal: Buy
Current Market Cap: $13.1M
For a thorough assessment of BCDA stock, go to TipRanks’ Stock Analysis page.